摘要
目的系统评价5-HTR2A 102T>C基因多态性与抗精神病药物疗效的相关性。方法计算机检索Web of Science、Pub Med、中国学术期刊全文数据库(CNKI)、万方数据库、维普数据库中研究5-HTR2A 102T>C基因多态性与抗精神病药物疗效的研究,检索年限从建库至2017年5月2日。按纳入与排除标准筛选文献、提取资料并评价纳入研究的方法学质量后,采用Stata 12.0软件进行Meta分析。结果共纳入10项研究,Meta-分析结果表明,5-HTR2A 102T>C基因多态性与抗精神病药物疗效在等位基因模型、共显性基因模型、显性基因模型中均无统计学意义(P>0.05):等位基因模型OR=1.16,95%CI(1.00~1.36);共显性基因(TT vs CC)模型OR=1.23,95%CI(0.91~1.65);共显性基因(TT vs TC)模型OR=0.90,95%CI(0.68~1.19);显性基因模型OR=1.04,95%CI(0.80~1.34);而隐性基因模型和超显性基因模型具有统计学意义(P<0.05):隐性基因模型OR=1.37,95%CI(1.09~1.72);超显性基因模型OR=0.78,95%CI(0.62~0.96)。结论 5-HTR2A 102T>C基因多态性与抗精神病药物疗效有关联性。
Objective To evaluate the correlation between the clinical efficacy ofantipsychotics and 5-HTR2Agene with 102T〉C point mutation. Methods The research data from the database of Web of Science, PubMed, CNKI, Wangfang, VIP were searched from the initial date to May 2, 2017 to collecte the published studies about the 5-HTR2A 102T〉C polymorphism on the effects ofantipsychotics. According to the inclusion and exclusion criteria, the studies were screened, the data were extracted, and methodological quality of the included studies was evaluated. Then Meta-analysis was conducted using Stata 12.0 software. Results A total of l0 studies were included. There was no significant association between 5-HTR2A gene with 102T〉C point mutation and the clinical efficacy of antipsychotics in allele gene model, codominant gene model （TT vs CC）, codominant gene model （TTvs TC）, and dominant gene model （P 〉 0.05）： allele gene model, OR=l.16, 95%CI （1.00-1.36）; codominant gene model （TTvs CC）, OR=1.23, 95%CI （0.91-1.65）; codominant gene model （TTvs TC）, OR=0.90, 95%CI （0.68-1.19）; dominant gene model, OR=l.04, 95%CI （0.80-1.34）; However, there was statistical significance in allogene gene model and super-dominant gene model （P 〈 0.05）： recessive gene model, OR=1.37, 95%CI （1.09-1.72）; super-dominant gene model, OR=0.78, 95%CI （0.62-0.96）. Conclusion 5-HTR2A gene with 102T〉C point variant has correlation with the clinical efficacy of antipsychotics.
作者
王丽萍
曾俊芬
宋金春
WANG Liping;ZENG Junfen;SONG Jinchun(Pharmacy Department of Renmin Hospital, Wuhan University, Wuhan 430060, Chin)
出处
《药物评价研究》
CAS
2018年第4期656-663,共8页
Drug Evaluation Research
基金
国家自然科学基金(31500281)
